Recurrent Glioblastoma Study – Now Enrolling
The reason for this study is to find out if the experimental study drug, tesevatinib, is effective as a possible treatment for recurrent glioblastoma. Certain genetic information about tumors will also be collected, by drawing blood, to help better understand why tesevatinib did or did not work in treating the recurrent glioblastoma.
Individuals enrolled will take tesevatinib daily as long as the cancer does not get worse and there are no severe or intolerable side effects. The last visit will be about 30 days after the last dose of tesevatinib. While on the study, individuals will not be able to take any other treatment for their cancer or be on any other clinical studies.
If you, your family member or loved one is interested in learning more about participating in this study, please contact the Study Coordinator at 520-320-2157.